RecruitingPhase 4NCT07442006
Glycemic Variability of Combination Therapies in T2DM
A Multicenter Study to Evaluate Efficacy and Safety
Sponsor
JW Pharmaceutical
Enrollment
178 participants
Start Date
Oct 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Glycemic Variability of Combination Therapies in T2DM
Eligibility
Min Age: 19 Years
Inclusion Criteria1
- Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.
Exclusion Criteria4
- History of acute or chronic metabolic acidosis
- Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²)
- Severe hepatic impairment
- History of heart failure (NYHA Class III/IV)
Interventions
DRUGMetformin
500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
DRUGEmpagliflozin/Linagliptin
10/5 mg, for 12 weeks (PO, QD)
DRUGEmpagliflozin/Metformin
5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
DRUGAnagliptin
100 mg, for 12 weeks (PO, BID)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07442006
Related Trials
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
NCT068364791 location
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
NCT069066406 locations
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
NCT069066276 locations
Investigation of Motor Imagery Ability, Body Awareness and Cognitive Functions in Type 2 Diabetes Mellitus
NCT065888941 location
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
NCT074652241 location